Reduced CDI Recurrence Observed With Investigational Microbiome Therapy
SER-109 contains purified bacterial spores of multiple Firmicute species obtained from the stool of healthy human donors.
Gastrohepatic Disorders
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Clinical Hold Lifted on Seladelpar for Chronic Liver Diseases
The FDA has lifted the clinical hold on 3 Investigational New Drug applications evaluating seladelpar (CymaBay Therapeutics) for the treatment of non-alcoholic steatohepatitis, primary biliary cholangitis and primary sclerosing cholangitis.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
MPR Weekly Dose Podcast Episode 43
This week: Significant moves in COVID-19 vaccine development; Research finds a link between PPI use and increased risk of COVID-19; We look at remdesivir’s efficacy in severe COVID cases; And several Company’s recall metformin extended release tablets.
FDA Committee Narrowly Votes in Favor of Terlipressin for Hepatorenal Syndrome Type 1
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 8 to 7 in favor of the approval of terlipressin for the treatment of adults with hepatorenal syndrome type 1
CRC Risk Down With ACEi, Angiotensin Receptor Blocker Use
Five percent reduction in adjusted hazard ratio risk with each single year increase in drug use.
MPR Weekly Dose Podcast Episode 39
This week we cover the latest in the rapidly shifting perception of chloroquine and hydroxychloroquine; The polio vaccine as a potential protector against COVID-19; A new approval for Gardasil 9; And the American Gastroenterological Association draw up new guidelines for probiotic use as a treatment in gastrointestinal disorders.
Lumasiran Granted Priority Review for Primary Hyperoxaluria Type 1
The FDA has accepted for Priority Review the New Drug Application for lumasiran for the treatment of primary hyperoxaluria type 1.
Updated Guidelines Issued for Management of Diverticulitis
CT scan is most appropriate initial imaging modality; lifestyle interventions can reduce risk.
